See more : Hvidbjerg Bank A/S (HVID.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Expand Energy Corporation (EXEEZ) Income Statement Analysis – Financial Results
- H.U. Group Holdings, Inc. (4544.T) Income Statement Analysis – Financial Results
- SynAct Pharma AB (SYNACT.ST) Income Statement Analysis – Financial Results
- Mohit Industries Limited (MOHITIND.BO) Income Statement Analysis – Financial Results
- Indaptus Therapeutics, Inc. (INDP) Income Statement Analysis – Financial Results
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 850.73M | 1.03B | 1.14B | 833.80M | 1.03B | 740.42M | 497.69M | 621.87M | 579.46M | 470.90M | 415.93M | 232.53M | 133.89M | 92.39M | 61.91M | 31.99M | 24.93M | 19.76M | 20.12M |
| Cost of Revenue | 70.63M | 84.06M | 80.96M | 62.84M | 73.34M | 76.30M | 54.79M | 46.51M | 50.01M | 36.82M | 32.41M | 23.56M | 23.03M | 18.70M | 16.19M | 12.21M | 10.88M | 9.41M | 12.09M |
| Gross Profit | 780.11M | 947.10M | 1.06B | 770.96M | 955.95M | 664.13M | 442.90M | 575.36M | 529.45M | 434.08M | 383.52M | 208.97M | 110.86M | 73.69M | 45.72M | 19.78M | 14.05M | 10.35M | 8.02M |
| Gross Profit Ratio | 91.70% | 91.85% | 92.90% | 92.46% | 92.87% | 89.70% | 88.99% | 92.52% | 91.37% | 92.18% | 92.21% | 89.87% | 82.80% | 79.76% | 73.86% | 61.83% | 56.35% | 52.37% | 39.89% |
| Research & Development | 243.76M | 226.85M | 224.39M | 139.27M | 127.82M | 114.28M | 110.43M | 95.05M | 110.12M | 105.07M | 68.11M | 45.31M | 32.89M | 23.82M | 22.11M | 16.00M | 15.86M | 15.57M | 24.44M |
| General & Administrative | 16.06M | 12.95M | 16.41M | 17.43M | 13.39M | 93.58M | 54.51M | 36.49M | 28.88M | 22.65M | 20.77M | 16.81M | 17.37M | 11.12M | 11.85M | 12.16M | 11.31M | 10.73M | 12.42M |
| Selling & Marketing | 255.58M | 554.63M | 599.70M | 426.93M | 530.57M | 350.47M | 253.00M | 349.84M | 309.04M | 258.03M | 232.06M | 126.62M | 54.60M | 52.65M | 30.48M | 21.70M | 18.99M | 0.00 | 0.00 |
| SG&A | 271.64M | 567.58M | 616.11M | 444.36M | 543.96M | 444.05M | 307.51M | 386.32M | 337.91M | 280.68M | 252.83M | 143.43M | 71.97M | 63.77M | 42.33M | 33.86M | 30.30M | 10.73M | 12.42M |
| Other Expenses | 167.61M | 29.12M | 30.41M | 22.98M | 33.53M | 1.61M | 965.00K | 1.03M | 2.87M | 931.00K | 75.00K | 24.00K | -34.61M | -20.83M | -13.67M | -7.85M | -943.00K | -448.00K | -2.90M |
| Operating Expenses | 683.02M | 823.55M | 870.91M | 606.61M | 705.31M | 530.87M | 382.93M | 431.87M | 391.89M | 312.69M | 279.35M | 146.92M | 70.25M | 66.76M | 50.77M | 42.01M | 41.99M | 31.66M | 39.78M |
| Cost & Expenses | 753.64M | 907.62M | 951.86M | 669.45M | 778.65M | 607.17M | 437.72M | 478.38M | 441.90M | 349.51M | 311.76M | 170.48M | 93.28M | 85.46M | 66.96M | 54.22M | 52.87M | 41.07M | 51.87M |
| Interest Income | 7.97M | 11.29M | 5.13M | 6.13M | 2.09M | 2.86M | 2.08M | 3.77M | 2.92M | 864.00K | 1.96M | 905.00K | 990.00K | 0.00 | 0.00 | 586.00K | 462.00K | 432.00K | 0.00 |
| Interest Expense | 3.07M | 1.54M | 1.06M | 5.60M | 6.30M | 6.49M | 6.08M | 4.06M | 7.13M | 1.87M | 5.44M | 6.17M | 4.86M | 2.95M | 2.55M | 1.48M | 1.25M | 448.00K | 2.90M |
| Depreciation & Amortization | 59.93M | 80.97M | 60.85M | 53.61M | 56.68M | 53.22M | 42.61M | 30.11M | 28.30M | 24.39M | 14.84M | 9.79M | 5.35M | 7.72M | 5.30M | 6.17M | 6.87M | 6.13M | 0.00 |
| EBITDA | 160.52M | 214.80M | 277.83M | 235.91M | 309.29M | 157.09M | 119.18M | 185.01M | 181.38M | 154.36M | 119.22M | 73.65M | 47.84M | 14.66M | 253.00K | -15.48M | -20.83M | -15.18M | -31.76M |
| EBITDA Ratio | 18.87% | 18.90% | 22.22% | 27.00% | 30.95% | 27.32% | 23.79% | 29.71% | 31.23% | 32.78% | 28.66% | 31.29% | 35.07% | 15.86% | 0.41% | -48.38% | -85.14% | -76.78% | -157.86% |
| Operating Income | 97.09M | 133.27M | 217.38M | 173.03M | 247.48M | 150.26M | 76.00M | 155.12M | 153.06M | 129.96M | 108.36M | 63.87M | 42.49M | 6.93M | -5.05M | -21.65M | -26.75M | -21.31M | -31.76M |
| Operating Income Ratio | 11.41% | 12.92% | 19.06% | 20.75% | 24.04% | 20.29% | 15.27% | 24.94% | 26.41% | 27.60% | 26.05% | 27.47% | 31.73% | 7.50% | -8.16% | -67.67% | -107.32% | -107.82% | -157.86% |
| Total Other Income/Expenses | 438.40K | -977.89K | -1.46M | 3.67M | -1.17M | 50.05M | -5.51M | -4.28M | -7.11M | -1.86M | -5.69M | -8.85M | -4.86M | -2.95M | -2.55M | -1.48M | -2.20M | -448.00K | -2.90M |
| Income Before Tax | 97.53M | 132.29M | 215.92M | 176.70M | 246.31M | 143.07M | 70.50M | 150.84M | 145.95M | 128.10M | 98.95M | 57.70M | 37.63M | 3.99M | -7.60M | -23.13M | -28.95M | -21.76M | -34.66M |
| Income Before Tax Ratio | 11.46% | 12.83% | 18.94% | 21.19% | 23.93% | 19.32% | 14.16% | 24.26% | 25.19% | 27.20% | 23.79% | 24.81% | 28.10% | 4.31% | -12.27% | -72.30% | -116.13% | -110.08% | -172.28% |
| Income Tax Expense | -10.92M | -4.98M | 3.54M | 12.44M | 25.66M | 13.30M | 10.34M | 20.83M | 18.90M | 17.61M | 15.41M | 5.26M | 5.26M | 2.80M | 879.00K | 1.07M | 1.71M | 273.00K | -4.30M |
| Net Income | 108.63M | 138.00M | 213.30M | 164.66M | 227.36M | 150.98M | 75.29M | 138.71M | 127.72M | 118.26M | 87.22M | 53.16M | 30.83M | 3.68M | -7.32M | -23.40M | -29.55M | -22.03M | -30.36M |
| Net Income Ratio | 12.77% | 13.38% | 18.71% | 19.75% | 22.09% | 20.39% | 15.13% | 22.30% | 22.04% | 25.11% | 20.97% | 22.86% | 23.02% | 3.98% | -11.82% | -73.15% | -118.55% | -111.47% | -150.90% |
| EPS | 0.11 | 0.13 | 0.21 | 0.17 | 0.25 | 0.16 | 0.08 | 0.15 | 0.14 | 0.13 | 0.10 | 0.07 | 0.04 | 0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | 0.11 | 0.13 | 0.20 | 0.17 | 0.25 | 0.16 | 0.08 | 0.15 | 0.14 | 0.13 | 0.10 | 0.07 | 0.04 | 0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 1.03B | 1.03B | 1.04B | 989.41M | 923.00M | 923.00M | 923.00M | 923.00M | 923.00M | 923.00M | 864.35M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M |
| Weighted Avg Shares Out (Dil) | 1.03B | 1.03B | 1.04B | 989.41M | 923.00M | 923.00M | 923.00M | 923.00M | 923.00M | 923.00M | 864.35M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M | 710.00M |
Source: https://incomestatements.info
Category: Stock Reports